Skip to main content
Premium Trial:

Request an Annual Quote

Cyntellect Gets $500,000 Grant to Develop Transfection Technology

Premium

Cyntellect announced this week that it has received a phase II SBIR grant worth $500,000 from the National Science Foundation to develop its laser-based transfection technology.

The technology — known as LEAP, or laser-enabling analysis and processing — involves temporarily permeabilizing cells with a laser so that a variety of molecules, including siRNAs, can be transfected. The laser is also used to destroy untransfected cells, so that researchers end up with a pure set of transfected cells.

The NSF grant — entitled High-Throughput Specific Cell Loading by Opto-Injection — is the fourth government grant the company has received since July for the LEAP platform, Cyntellect vice president of R&D and COO Fred Koller told RNAi News. Together, these grants total $2.25 million, he said.

Cyntellect is in the process of running pilot studies of the LEAP platform for potential purchasers of the system.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.